Now that the so-called double chin shot has been approved by the United States Food and Drug Administration (FDA), the developer of the Kybella drug is expected to be raking in the cash now that their ATX 101 injection has been proven to work. But how much exactly is Kythera Biopharmaceuticals Inc. expected to make based upon this FDA approval?
In a related report by the Inquisitr, since the 2007 medical trials began, Florida dermatologist Dr. Susan Weinkle has been working with the double chin shot since it was first called the ATX 101. Now that it is officially known as Kybella, she claims the double chin cure has worked well for the 2,600 patients who received the injections.
“Options at the moment for submental fat [double chins] are [to] cut it out or suck it out,” says Dr. Weinkle. “However, this is going to be a noninvasive in-the-office procedure that can be performed by your dermatologist and excellent results.”
The double chin shot does require multiple treatments in order to be effective, but patient Ashley Gallagher says she noticed her fat chin receding almost immediately.
“I was cute as button — and there was my double chin,” she said, according to the New York Times. “I noticed a dramatic difference [after taking the double chin cure]. It was receding.”
Dr. Rod J. Rohrich, a professor of plastic surgery at the University of Texas Southwestern Medical Center in Dallas, says there will be a large market for the double chin shot since it does not require invasive surgery and it is actually cheaper than a facelift or a neck lift.
“For highly selected patients who have under-chin fat without sagging skin, this will work,” said Dr. Rohrich. “So many consumers don’t want a knife, they want a needle. We are basically wimps.”
Kythera Biopharmaceuticals believes their double chin shot could generate hundreds of millions of dollars per year. According to the Wall Street Journal, the double chin is an often complained about, yet undertreated aesthetic complaint, which results in an older and heavier facial appearance. The company reported that consumers “spent nearly $12 billion on more than 11 million physician-administered surgical and nonsurgical aesthetic procedures in the U.S. in 2013,” with non-surgical procedures accounting for 84 percent of that total amount. Although a double chin treatment will cost upwards of $2,000, it’s expected by analysts that Kybella could bring in more than $300 million a year at its peak.
But buyer beware. The FDA may have approved this double chin shot, but they do admit to potential side effects.
“Treatment with Kybella should only be provided by a licensed health care professional, and patients should fully understand the risks associated with use of the drug before considering treatment,” Dr. Amy Egan of the FDA said in a statement. “It is important to remember that Kybella is only approved for the treatment of fat occurring below the chin, and it is not known if Kybella is safe or effective for treatment outside of this area.”
Patients in the medical trial reported bruising, pain, numbness, and swelling, with the worst symptom being difficulty with swallowing.
Do you think the double chin shot is a good idea, or would you rather see your friends and relatives hit the gym rather than go to the doctor for a quick fix?